Web Analytics

3 Latest Announced Rounds

  • $10,500,000
    Unknown

    3 Investors

    HVAC and Refrigeration Equipment Manufacturing
    Nov 5th, 2024
  • $4,000,000
    Series A
    Financial Services
    Nov 5th, 2024
  • $1,000,000
    Pre-Seed

    1 Investors

    Data Infrastructure and Analytics
    Nov 5th, 2024
$1,349.98M Raised in 67 Funding Rounds in the past 7 Days - View All

Funding Round Profile

TILT Biotherapeutics Ltd

start up
Finland - Helsinki
  • 08/02/2023
  • Unknown
  • $23,611,000

TILT Biotherapeutics Ltd is a clinical stage company working in oncology towards enabling T-cell therapies and immune checkpoint inhibitors with oncolytic viruses.

Embodiments of the technology will be used to enhance tumor infiltrating lymphocytes (TILs), chimeric antigen receptor T cells (CAR T) and immune checkpoint inhibiting antibody therapies.

TILT was founded by Pr. Akseli Hemminki, who has published hundreds of papers in the field and treated almost 300 patients with 10 different oncolytic viruses. In 2013, Pr. Hemminki started his second company, TILT Biotherapeutics Ltd, with a technology based on his past findings in the lab, but more importantly in the clinic. The research conducted by TILT alone or in collaboration with some of world’s leading research groups with synergic technologies has generated very excellent results. The lead candidate is a clinical stage TNFα/IL2 armed oncolytic adenovirus (TILT-123 or Ad5/3-E2F-delta24-hTNFα-IRES-hIL2).

Multiple Phase I clinical trials are ongoing.

For contact: BD (at) tiltbio.com


Related People

Akseli HemminkiFounder

Akseli Hemminki Finland - Helsinki, Uusimaa

N/A